Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODERATO Study
2023-510439-13-00Phase 3Authorised
- Sponsor
- OCUS Innovation
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of atropine in myopia (3 arms), sponsored by OCUS Innovation. Primary endpoint: Mean annual rate of progression of myopia based on spherical equivalent. Planned start Jan 2025; status: authorised.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on 2023-510439-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510439-13-00.